Today we are watching…
1. Johnson & Johnson (#jnj)
Investors are combing the markets for the firm most likely to produce a cure to coronavirus. It may be sitting right under our noses. Blue-chip pharmaceutical player Johnson & Johnson has the capacity to circulate a jab to over one billion people and says it has the formula in development behind the scenes. Human testing and federal approval could come as early as September, which is why the US government has agreed to give the company a massive cash injection to speed up the process. This is a matter of life or death!
2. Moody’s (#moody)
This credit rating agency, one of three dominant players, just looked at the USA’s growing corporate debt-pile and winced. Moody’s has downgraded its assessment of the borrowed money from stable to negative, concerned that consumer-reliant brands won’t get the business they need to pay all the dues. Since the financial crisis, low-interest rates have helped corporate debt issuance rise 78%. Following this news, investors might start looking for companies that operate as if they are allergic to the stuff!